官方服务：
资源简介：
Treatment effect of PCSK9 inhibitors.
应用场景：
创建时间：
2019-01-16
相关数据集
PCSK9(deltaCRD) in complex with cyclic peptide 83
PCSK9(deltaCRD) in complex with cyclic peptide 83 Descriptor: GLYCEROL, Peptide 83, Proprotein convertase subtilisin/kexin type 9 Authors: Orth, P. Deposit date: 2020-06-19 Release date: 2020-11-18 La
Protein Data Bank Japan2024-07-10 更新70
PCSK9 in complex with an inhibitor
PCSK9 in complex with an inhibitor Descriptor: CALCIUM ION, DGN-DVA-YC3-GLU-PRO-THR-THR-PHE-MAA-A1BC0 inhibitor, Proprotein convertase subtilisin/kexin type 9 Authors: Xu, M, Chopra, R. Deposit date:
Protein Data Bank Japan2025-04-30 更新50
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor
Peptides are regarded as promising next-generation therapeutics. However, an analysis of over 1000 bioactive peptide candidates suggests that many have underdeveloped affinities and could benefit from
NIAID Data Ecosystem30
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound
NIAID Data Ecosystem50
Supplementary Material for: A Temporal Association Between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitor: A Case Report
Introduction: We aim to report the clinical course of a patient with pachychoroidopathy who experienced regression of subfoveal drusen during cholesterol treatment using PCSK9 inhibitors. Case present
NIAID Data Ecosystem50
